Malignant urinary system neoplasm
MONDO:0006295A primary or metastatic malignant tumor involving the urinary system. Common tumor types include carcinomas, lymphomas, and sarcomas.
Also known as: cancer of renal system, malignant neoplasm of renal system, malignant renal system neoplasm, malignant urinary system neoplasm, malignant urinary tract neoplasm, renal system cancer, urinary system cancer
4258 clinical trials for this condition and its sub-types, 75 tagged with Malignant urinary system neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Malignant urinary system neoplasm
-
Kidney cancer 244 trials · 851 incl. sub-types
8 sub-types
- Renal carcinoma 85 trials · 764 incl. sub-types Sub-types →
- Childhood malignant kidney neoplasm 0 trials · 30 incl. sub-types Sub-types →
- Malignant renal pelvis neoplasm 6 trials · 23 incl. sub-types Sub-types →
- Kidney Wilms tumor 9 trials · 11 incl. sub-types Sub-types →
- Kidney sarcoma 0 trials · 8 incl. sub-types Sub-types →
- Mesoblastic nephroma 4 trials Sub-types →
- Graham-Boyle-Troxell syndrome 0 trials
- Malignant mixed epithelial stromal tumor of the kidney 0 trials
-
Urothelial carcinoma 363 trials · 692 incl. sub-types
5 sub-types
- Bladder transitional cell carcinoma 130 trials · 408 incl. sub-types Sub-types →
- Renal pelvis/ureter urothelial carcinoma 65 trials · 78 incl. sub-types Sub-types →
- Urethra transitional cell carcinoma 17 trials Sub-types →
- Pure squamous carcinoma of the urothelial tract 1 trial
- Non-papillary transitional cell carcinoma of the bladder 0 trials
-
Urinary bladder cancer 39 trials · 682 incl. sub-types
9 sub-types
- Urinary bladder carcinoma 392 trials · 669 incl. sub-types Sub-types →
- Urachus cancer 3 trials · 6 incl. sub-types Sub-types →
- Bladder dome cancer 0 trials Sub-types →
- Bladder lateral wall cancer 0 trials
- Bladder lymphoma 0 trials
- Bladder neck cancer 0 trials
- Bladder sarcoma 0 trials
- Urinary bladder anterior wall cancer 0 trials
- Urinary bladder posterior wall cancer 0 trials
-
Infiltrating urothelial carcinoma 5 trials · 185 incl. sub-types
2 sub-types
- Infiltrating bladder urothelial carcinoma 181 trials · 183 incl. sub-types Sub-types →
- Infiltrating renal pelvis/ureter urothelial carcinoma 2 trials Sub-types →
-
Ureter cancer 27 trials · 34 incl. sub-types
3 sub-types
- Ureter carcinoma 1 trial · 19 incl. sub-types Sub-types →
- Ureteral lymphoma 0 trials
- Ureteric orifice cancer 0 trials
-
Urethra cancer 18 trials · 29 incl. sub-types
5 sub-types
- Carcinoma of urethra 2 trials · 21 incl. sub-types Sub-types →
- Anterior urethra cancer 0 trials
- Female urethral cancer 0 trials
- Male urethral cancer 0 trials Sub-types →
- Posterior urethra cancer 0 trials
-
Multiple endocrine neoplasia type 2B 2 trials
-
Malignant prostate phyllodes tumor 0 trials
Most studied deeper sub-types
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo aims to boost immune system against hard-to-treat urinary cancers
Disease control OngoingThis early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in 100 adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination can help the immune system fight cancer better…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Scientists reprogram immune cells to attack common cancer mutation
Disease control OngoingThis early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Immunotherapy duo takes on rare cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink tumors in people with rare cancers of the urinary or reproductive systems. About 100 adults with advanced disease that cannot be removed by surgery are taking part. The main goal is t…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Head-to-Head drug battle for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for immunotherapy side effects: which drug works best for colitis?
Disease control OngoingThis study compares two medications, infliximab and vedolizumab, to treat colitis (colon inflammation) caused by immune checkpoint inhibitor therapy in cancer patients. About 47 adults with genitourinary cancer, melanoma, or non-small cell lung cancer are participating. The goal …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…
Phase 3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted drug shows promise for Hard-to-Treat bladder cancers
Disease control OngoingThis study tests a drug called olaparib in 60 people with advanced bladder or related cancers that have specific DNA repair defects. Olaparib blocks a protein that cancer cells need to fix their DNA, which may stop the cancer from growing. The goal is to see if the drug can shrin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a testosterone shot before surgery speed recovery?
Disease control OngoingThis early-phase trial is testing whether giving testosterone replacement therapy to men with low testosterone before and after major urologic surgery is safe and might improve recovery. Researchers will track quality of life, frailty, complications, hospital stay length, and rea…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Bacteria bombs target stubborn tumors in new cancer combo trial
Disease control OngoingThis study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug BL-B01D1 tested in tiny early trial for tough cancers
Disease control OngoingThis early-phase study tests a new drug called BL-B01D1 in people with advanced urinary or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and get a first look at whether it might shrink tumors…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Wearable tech could spot Post-Surgery problems early
Symptom relief OngoingThis trial tests whether a home-based telemonitoring program, which tracks symptoms and daily steps using a wearable device and app, can improve recovery and reduce complications within 30 days after abdominal surgery for gastrointestinal, genitourinary, or gynecologic cancers. P…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can a new therapy help cancer patients kick the habit?
Symptom relief OngoingThis study compares a new counseling approach called Acceptance and Commitment Therapy (ACT) with standard counseling to help people with head and neck, lung, breast, gastrointestinal, or genitourinary cancer stop smoking. About 51 adults who smoke at least one cigarette per day …
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Remote exercise and education program aims to boost Well-Being in older cancer patients
Symptom relief OngoingThis study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …
Sponsor: Martine Puts • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New program helps cancer patients and caregivers talk through tough emotions
Symptom relief OngoingThis study tests a communication program for people with advanced cancer and their caregivers. The goal is to help them manage difficult emotions and talk about the patient's illness and treatment wishes. About 45 participants will take part, and the program is tailored for Latin…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Tumor testing could unlock personalized cancer treatments
Knowledge-focused OngoingThis study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
New breathing technique tested in robotic cancer surgery
Knowledge-focused CancelledThis study aimed to compare a newer breathing machine method (APRV) with the standard method (CMV) during anesthesia for robotic gynecologic or genitourinary cancer surgery. The goal was to find the best settings to help patients' lungs work well during the procedure. However, th…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests could reveal who reacts differently to radiation
Knowledge-focused OngoingThis study looks at blood samples from 25 cancer patients receiving radiation therapy. Researchers want to find specific genes that show how each person's body responds to radiation. The goal is to better understand individual reactions and possibly personalize radiation treatmen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists hunt for clues to predict which cancer treatments work best
Knowledge-focused OngoingThis study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancers. Researchers analyze these samples to find genetic markers that predict how well different treatments will work. Participants do not receive any experimental treatment …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New CT scanner could sharpen cancer radiation treatments
Knowledge-focused OngoingThis pilot study tests a new FDA-approved cone-beam CT imaging system (Halcyon 4.0) for planning radiation therapy. Researchers will compare its image quality and ease of use to standard CT scans in 27 adults with various cancers. The goal is to see if the new system can improve …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:01 UTC